论文部分内容阅读
目的:观察肾同种移植排斥患者血清可溶性TRAIL(sTRAIL)、sTNFR-I、sTNFR-II、sFas、sFasL的水平变化与临床意义。方法:采用酶联免疫双抗体夹心法测定。结果:受试组(n=29)与健康对照组(n=29)比较sTRAIL、sTNFR-I、sTNFR-II、sFas差异有显著性(P<0.01)。受试组与对照组(n=58)sFasL比较差异无显著性(P>0.05)。结论:肾同种移植排斥患者血清sTRAIL、sTNFR-I、sTNFR-II、sFas水平比对照组显著升高,提示血清这些细胞因子的含量变化在肾同种移植排斥病理过程中起着重要作用。
Objective: To observe the changes and clinical significance of serum soluble TRAIL (sTRAIL), sTNFR-I, sTNFR-II, sFas and sFasL in renal allograft rejection patients. Methods: The enzyme-linked immunosorbent assay sandwich method. Results: The differences of sTRAIL, sTNFR-I, sTNFR-II and sFas in the test group (n = 29) and the healthy control group (n = 29) were significant (P <0.01). There was no significant difference in sFasL between test group and control group (n = 58) (P> 0.05). Conclusion: The levels of serum sTRAIL, sTNFR-I, sTNFR-II and sFas in renal allograft rejection patients are significantly higher than those in control group, suggesting that serum cytokines levels play an important role in renal allograft rejection pathology.